PUMA BIOTECHNOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4 USD | +0.25% |
|
-8.47% | -7.62% |
| May. 17 | Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial | RE |
| May. 02 | Transcript : Puma Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024 |
Evolution of the average Target Price on Puma Biotechnology, Inc.
Price target over the last 5 years
History of analyst recommendation changes
0aec899a1405ce02fe24625753f6cf0._si4-n6UNenoD4YxMGY2UwZUVQJTn9k-dMWCAdDjNQg.mPzvtBTWd6aibM9JZAoHZCs3JWcd3o9UNuj2bILWRmqVj9TCG_V9jKdbyw~ab0f1d5ef31718b6271098830634f8f6
More recommendations
Analysts' Consensus
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
4
USD
Average target price
4.333
USD
Spread / Average Target
+8.33%
High Price Target
7
USD
Spread / Highest target
+75.00%
Low Price Target
2
USD
Spread / Lowest Target
-50.00%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Puma Biotechnology, Inc.
| HC Wainwright | |
| Citigroup | |
| RBC Capital Markets |
Trading Rating
Investor Rating
ESG Refinitiv
C+
EPS Revisions
- Stock Market
- Equities
- PBYI Stock
- Consensus Puma Biotechnology, Inc.
